Stifel Financial
RAPT

Stifel Financial’s RAPT Therapeutics RAPT Stock Holding History

Stifel Financial’s Portfolio RAPT Stock Details RAPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-2,178
Closed -$53.1K – 3444
2024
Q2 		$53.1K Buy
+2,178
New +$101K ﹤0.01% 3276

Other funds holding RAPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Stifel Financial's RAPT Position: Q3 2024 in Review

Stifel Financial sold out of RAPT Therapeutics (RAPT) in Q3 2024, closing a stake of 2,178 shares — an estimated $53.1K sold.

Stifel Financial first reported a position in RAPT in Q2 2024 and held it in 1 quarter. The position peaked at $53.1K in Q2 2024. 94 funds tracked by Wall St. Rank hold RAPT as of Q3 2024.

  • Stifel Financial reported no remaining RAPT Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Stifel Financial sold 2,178 RAPT Therapeutics shares in Q3 2024, an estimated $53.1K.
  • Stifel Financial first reported a position in RAPT Therapeutics in Q2 2024 and held it in 1 quarter.
  • Stifel Financial's RAPT Therapeutics position peaked at $53.1K in Q2 2024.
  • 94 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q3 2024.

Based on Stifel Financial's 13F filing for Q3 2024, filed 14 Nov 2024.